Comparative Pharmacology
Head-to-head clinical analysis: ELAVIL versus PRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAVIL versus PRAMINE.
ELAVIL vs PRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic concentrations. It also exhibits anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentration in the synaptic cleft.
Oral: Initial 75 mg/day in divided doses or 50-100 mg at bedtime; increase to 150 mg/day; maximum 300 mg/day. IM: 20-30 mg q6h, switch to oral as soon as possible.
Imipramine (PRAMINE) 75-150 mg orally once daily at bedtime, titrated from 25-50 mg, max 300 mg/day.
None Documented
None Documented
Clinical Note
moderateImipramine + Torasemide
"The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide."
Clinical Note
moderateClomipramine + Torasemide
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide."
Clinical Note
moderateImipramine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid."
Clinical Note
moderateClomipramine + Etacrynic acid
10–50 hours (mean ~20 hours); terminal elimination half-life is prolonged in elderly and patients with hepatic impairment; steady-state achieved in 7–21 days.
10-12 hours (terminal elimination half-life; may be prolonged in elderly and hepatic impairment)
Renal (approximately 40% as metabolites, <5% unchanged); biliary/fecal (approximately 60% as metabolites, including glucuronide conjugates).
Renal: 70% (as metabolites); Fecal: 30% (as metabolites and unchanged drug)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid."